Home/ Crypto News/ Novartis (NVS) Stock Drops 3% as Pelacarsen Heart Drug Disappoints in Key Trial

blockonomi 1 week ago

Novartis (NVS) Stock Drops 3% as Pelacarsen Heart Drug Disappoints in Key Trial

Stocks

Novartis (NVS) stock dropped 3% after pelacarsen failed its cardiovascular outcomes trial, raising concerns about Lp(a)-targeting therapies.

The post Novartis (NVS) Stock Drops 3% as Pelacarsen Heart Drug Disappoints in Key Trial appeared first on Blockonomi.

Source: Source: Blockonomi